ONO-4578 + letrozole + Palbociclib + abemaciclib
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor-positive Breast Cancer
Conditions
Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Trial Timeline
Nov 9, 2021 → Apr 30, 2026
NCT ID
NCT06570031About ONO-4578 + letrozole + Palbociclib + abemaciclib
ONO-4578 + letrozole + Palbociclib + abemaciclib is a phase 1 stage product being developed by Ono Pharmaceutical for Hormone Receptor-positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06570031. Target conditions include Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Hormone Receptor-positive Breast Cancer were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06570031 | Phase 1 | Active |
Competing Products
20 competing products in Hormone Receptor-positive Breast Cancer